9. Indexation9. Indexation

9. Indexation

(1) At the start of 1 July 2025 (the indexation time), each amount covered by subsection (2) is replaced by the amount worked out using the following formula: 1.024 multiplied by the amount immediately before the indexation time Note: The indexed fees could in 2025 be viewed on the Department of Health and Aged Care’s MBS Online website (https://www.mbsonline.gov.au). (2) The amounts covered by this subsection are the fee for each item in a Schedule of this Determination. (3) An amount worked out under subsection (1) is to be rounded up or down to the nearest 5 cents (rounding down if the amount is an exact multiple of 2.5 cents).

Schedule – relevant services

<table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><thead><tr><td colspan="3" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; page-break-after:avoid; line-height:12pt"><span style="font-size:10pt; font-weight:bold">Group T1</span><span style="font-size:10pt; font-weight:bold; background-color:#ffffff">—</span><span style="font-size:10pt; font-weight:bold">Miscellaneous Therapeutic Procedures</span></p></td></tr><tr><td style="width:15.56%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; page-break-after:avoid; line-height:12pt"><span style="font-size:10pt; font-weight:bold">Column 1</span></p><p style="margin-top:3pt; page-break-after:avoid; line-height:12pt"><span style="font-size:10pt; font-weight:bold">Item</span></p></td><td style="width:65.72%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; page-break-after:avoid; line-height:12pt"><span style="font-size:10pt; font-weight:bold">Column 2</span></p><p style="margin-top:3pt; page-break-after:avoid; line-height:12pt"><span style="font-size:10pt; font-weight:bold">Description</span></p></td><td style="width:18.72%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; margin-left:29.7pt; page-break-after:avoid; line-height:12pt"><span style="font-size:10pt; font-weight:bold">Column 3</span></p><p style="margin-top:3pt; margin-left:29.7pt; page-break-after:avoid; line-height:12pt"><span style="font-size:10pt; font-weight:bold">Fee ($)</span></p></td></tr><tr><td colspan="3" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; page-break-after:avoid; line-height:12pt"><span style="font-size:10pt; font-weight:bold">Subgroup 8—Haematology</span></p></td></tr></thead><tbody><tr style="height:84.85pt"><td style="width:15.56%; border-top:1.5pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; line-height:normal; font-size:10pt"><span>13761</span></p></td><td style="width:65.72%; border-top:1.5pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:6pt; margin-left:18pt; line-height:normal; background-color:#ffffff"><a id="_Hlk140565262"><span>Extracorporeal photopheresis for the treatment of chronic graft</span><span>‑</span><span>versus</span><span>‑</span><span>host disease, if:</span></a></p><div style="margin-left:18pt; background-color:#ffffff"><p style="margin-left:18pt; text-indent:-18pt; line-height:normal"><span>(a)</span><span style="width:5.79pt; text-indent:0pt; display:inline-block"> </span><span>the person is:</span></p></div><div style="margin-left:43pt; background-color:#ffffff"><p style="margin-left:21.25pt; text-indent:-21.25pt; line-height:12pt"><span>(i)</span><span style="width:10.87pt; text-indent:0pt; display:inline-block"> </span><span>has received allogeneic haematopoietic stem cell transplantation; and</span></p></div><div style="margin-left:41.1pt; background-color:#ffffff"><p style="margin-left:23.15pt; text-indent:-23.15pt; line-height:12pt"><span>(ii)</span><span style="width:9.71pt; text-indent:0pt; display:inline-block"> </span><span>has been diagnosed with chronic</span><span>‑</span><span>graft</span><span>‑</span><span>versus host disease following the transplantation; and</span></p></div><div style="margin-left:41.1pt; background-color:#ffffff"><p style="margin-left:23.15pt; text-indent:-23.15pt; line-height:12pt"><span>(iii)</span><span style="width:6.66pt; text-indent:0pt; display:inline-block"> </span><span>steroid treatment is clinically unsuitable as the disease is steroid refractory or the person is steroid</span><span>‑</span><span>dependent or steroid</span><span>‑</span><span>intolerant; and</span></p></div><div style="margin-left:18pt; background-color:#ffffff"><p style="margin-left:18pt; text-indent:-18pt; line-height:normal"><span>(b)</span><span style="width:5.17pt; text-indent:0pt; display:inline-block"> </span><span>the person has not previously received extracorporeal photopheresis treatment; and</span></p></div><div style="margin-left:18pt; background-color:#ffffff"><p style="margin-left:18pt; text-indent:-18pt; line-height:normal"><span>(c)</span><span style="width:5.79pt; text-indent:0pt; display:inline-block"> </span><span>the service is delivered using an integrated, closed extracorporeal photopheresis system; and</span></p></div><div style="margin-left:18pt; background-color:#ffffff"><p style="margin-left:18pt; text-indent:-18pt; line-height:normal"><span>(d)</span><span style="width:5.17pt; text-indent:0pt; display:inline-block"> </span><span>the service is provided in combination with the use of methoxsalen that is listed on the Pharmaceutical Benefits Scheme; and</span></p></div><div style="margin-left:18pt; background-color:#ffffff"><p style="margin-left:18pt; text-indent:-18pt; line-height:normal"><span>(e)</span><span style="width:5.79pt; text-indent:0pt; display:inline-block"> </span><span>the service is provided by, or on behalf of, a specialist or consultant physician who:</span></p></div><div style="margin-left:45.2pt; background-color:#ffffff"><p style="margin-left:19.05pt; text-indent:-19.05pt; line-height:12pt"><span>(i)</span><span style="width:8.67pt; text-indent:0pt; display:inline-block"> </span><span>is practising in the speciality of haematology or oncology; and</span></p></div><div style="margin-left:45.2pt; background-color:#ffffff"><p style="margin-left:19.05pt; text-indent:-19.05pt; line-height:12pt"><span>(ii)</span><span style="width:5.61pt; text-indent:0pt; display:inline-block"> </span><span>has experience with allogeneic bone marrow transplantation.</span></p></div><p style="margin-top:12pt; margin-left:16.35pt; margin-bottom:12pt; page-break-inside:avoid; page-break-after:avoid"><span>Applicable once per treatment session (H)</span></p></td><td style="width:18.72%; border-top:1.5pt solid #000000; border-bottom:0.75pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; margin-left:29.7pt; margin-bottom:3pt; page-break-after:avoid; line-height:115%; font-size:10pt"><span>1,908.35</span></p></td></tr><tr style="height:204pt"><td style="width:15.56%; border-top:0.75pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; line-height:normal; font-size:10pt"><span>13762</span></p></td><td style="width:65.72%; border-top:0.75pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:6pt; margin-left:17.85pt; line-height:normal; background-color:#ffffff"><a id="_Hlk140565379"><span>Extracorporeal photopheresis for the treatment of chronic graft</span><span>‑</span><span>versus</span><span>‑</span><span>host disease, if:</span></a></p><div style="margin-left:18pt; background-color:#ffffff"><p style="margin-left:18pt; text-indent:-18pt; line-height:normal"><span>(a)</span><span style="width:5.79pt; text-indent:0pt; display:inline-block"> </span><span>the person is:</span></p></div><div style="margin-left:43pt; background-color:#ffffff"><p style="margin-left:21.25pt; text-indent:-21.25pt; line-height:12pt"><span>(i)</span><span style="width:10.87pt; text-indent:0pt; display:inline-block"> </span><span>has received allogeneic haematopoietic stem cell transplantation; and</span></p></div><div style="margin-left:43pt; background-color:#ffffff"><p style="margin-left:21.25pt; text-indent:-21.25pt; line-height:12pt"><span>(ii)</span><span style="width:7.81pt; text-indent:0pt; display:inline-block"> </span><span>has been diagnosed with chronic graft versus host disease following the transplantation; and</span></p></div><div style="margin-left:43pt; background-color:#ffffff"><p style="margin-left:21.25pt; text-indent:-21.25pt; line-height:12pt"><span>(iii)</span><span style="width:4.76pt; text-indent:0pt; display:inline-block"> </span><span>steroid treatment is clinically unsuitable as the disease is steroid refractory or the person is steroid</span><span>‑</span><span>dependent or steroid</span><span>‑</span><span>intolerant; and</span></p></div><div style="margin-left:18pt; background-color:#ffffff"><p style="margin-left:18pt; text-indent:-18pt; line-height:normal"><span>(b)</span><span style="width:5.17pt; text-indent:0pt; display:inline-block"> </span><span>the person has previously received an extracorporeal photopheresis treatment cycle and</span><span> </span><span>had a partial or complete response in at least one organ in response to treatment; and</span></p></div><div style="margin-left:18pt; background-color:#ffffff"><p style="margin-left:18pt; text-indent:-18pt; line-height:normal"><span>(c)</span><span style="width:5.79pt; text-indent:0pt; display:inline-block"> </span><span>the person requires further extracorporeal photopheresis; and</span></p></div><div style="margin-left:18pt; background-color:#ffffff"><p style="margin-left:18pt; text-indent:-18pt; line-height:normal"><span>(d)</span><span style="width:5.17pt; text-indent:0pt; display:inline-block"> </span><span>the service is delivered using an integrated, closed extracorporeal photopheresis system; and</span></p></div><div style="margin-left:18pt; background-color:#ffffff"><p style="margin-left:18pt; text-indent:-18pt; line-height:normal"><span>(e)</span><span style="width:5.79pt; text-indent:0pt; display:inline-block"> </span><span>the service is provided in combination with the use of methoxsalen that is listed on the Pharmaceutical Benefits Scheme; and</span></p></div><div style="margin-left:18pt; background-color:#ffffff"><p style="margin-left:18pt; text-indent:-18pt; line-height:normal"><span>(f)</span><span style="width:7.01pt; text-indent:0pt; display:inline-block"> </span><span>the service is provided by, or on behalf of, a specialist or consultant physician who:</span></p></div><div style="margin-left:45.2pt; background-color:#ffffff"><p style="margin-left:19.05pt; text-indent:-19.05pt; line-height:12pt"><span>(i)</span><span style="width:8.67pt; text-indent:0pt; display:inline-block"> </span><span>is practising in the speciality of haematology or oncology; and</span></p></div><div style="margin-left:45.2pt; background-color:#ffffff"><p style="margin-left:19.05pt; text-indent:-19.05pt; line-height:12pt"><span>(ii)</span><span style="width:5.61pt; text-indent:0pt; display:inline-block"> </span><span>has experience with allogeneic bone marrow transplantation.</span></p></div><p style="margin-top:12pt; margin-left:16.35pt; margin-bottom:12pt; page-break-inside:avoid; page-break-after:avoid"><span>Applicable once per treatment session (H)</span></p></td><td style="width:18.72%; border-top:0.75pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.35pt; padding-left:5.35pt; vertical-align:top; background-color:#ffffff"><p style="margin-top:3pt; margin-left:29.7pt; margin-bottom:3pt; page-break-after:avoid; line-height:115%; font-size:10pt"><span>1,908.35</span></p></td></tr></tbody></table>